MCID: MLG002
MIFTS: 49

Malignant Peritoneal Mesothelioma

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Malignant Peritoneal Mesothelioma

MalaCards integrated aliases for Malignant Peritoneal Mesothelioma:

Name: Malignant Peritoneal Mesothelioma 59
Diffuse Malignant Peritoneal Mesothelioma 59
Primary Malignant Peritoneal Mesothelioma 59
Malignant Mesothelioma of Peritoneum 73

Characteristics:

Orphanet epidemiological data:

59
malignant peritoneal mesothelioma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (France),1-9/100000 (Europe),1-9/1000000 (Italy); Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Orphanet 59 ORPHA168811
UMLS via Orphanet 74 C0346109
ICD10 via Orphanet 34 C45.1
UMLS 73 C0346109

Summaries for Malignant Peritoneal Mesothelioma

MalaCards based summary : Malignant Peritoneal Mesothelioma, also known as diffuse malignant peritoneal mesothelioma, is related to peritoneal mesothelioma and squamous cell carcinoma, and has symptoms including abdominal pain An important gene associated with Malignant Peritoneal Mesothelioma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Pathways in cancer. The drugs Doxorubicin and Doxil have been mentioned in the context of this disorder. Affiliated tissues include colon, lung and lymph node, and related phenotypes are dyspnea and ascites

Related Diseases for Malignant Peritoneal Mesothelioma

Diseases in the Peritoneal Mesothelioma family:

Benign Peritoneal Mesothelioma Malignant Peritoneal Mesothelioma

Diseases related to Malignant Peritoneal Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 173)
# Related Disease Score Top Affiliating Genes
1 peritoneal mesothelioma 32.3 CDKN2A EGFR MUC1 NF2
2 squamous cell carcinoma 29.9 CDKN2A EGFR MUC1
3 li-fraumeni syndrome 29.8 CDKN2A EGFR
4 adenocarcinoma 29.6 BIRC5 CDKN2A EGFR MUC1
5 renal cell carcinoma, nonpapillary 29.5 EGFR MUC1 VIM
6 lung cancer susceptibility 3 29.4 BIRC5 CDKN2A EGFR MUC1
7 benign mesothelioma 10.4
8 anaplastic oligodendroglioma 10.2 CDKN2A EGFR
9 ovarian cancer 10.2
10 basaloid squamous cell carcinoma 10.1 CDKN2A EGFR
11 cervical adenosquamous carcinoma 10.1 CDKN2A EGFR
12 optic nerve sheath meningioma 10.1 CDKN2A NF2
13 cornea cancer 10.1 CDKN2A NF2
14 pre-malignant neoplasm 10.1 CDKN2A EGFR
15 vulva cancer 10.1 CDKN2A EGFR
16 atypical neurofibroma 10.1 CDKN2A NF2
17 laryngeal disease 10.1 CDKN2A EGFR
18 oropharynx cancer 10.1 CDKN2A EGFR
19 pharynx cancer 10.1 CDKN2A EGFR
20 pleural cancer 10.1 CDKN2A NF2
21 penile cancer 10.1 CDKN2A EGFR
22 in situ carcinoma 10.1 CDKN2A EGFR
23 optic nerve neoplasm 10.1 CDKN2A NF2
24 esophageal disease 10.1 CDKN2A EGFR
25 liposarcoma 10.1 CDKN2A VIM
26 supratentorial cancer 10.1 CDKN2A EGFR
27 cerebrum cancer 10.1 CDKN2A EGFR
28 ameloblastic carcinoma 10.1 CDKN2A VIM
29 small cell carcinoma 10.1 CDKN2A EGFR
30 cellular schwannoma 10.1 CDKN2A NF2
31 sarcomatoid mesothelioma 10.1 CDKN2A VIM
32 adenosquamous lung carcinoma 10.1 BIRC5 EGFR
33 grade iii astrocytoma 10.1 CDKN2A EGFR
34 cervical intraepithelial neoplasia 10.1 BIRC5 CDKN2A
35 endocervical adenocarcinoma 10.1 CDKN2A VIM
36 benign meningioma 10.1 BIRC5 NF2
37 salivary gland carcinoma 10.1 CDKN2A EGFR
38 ovarian cancer 1 10.1
39 inguinal hernia 10.1
40 thrombosis 10.1
41 thrombocytosis 10.1
42 seminoma 10.1
43 peritonitis 10.1
44 intestinal obstruction 10.1
45 laryngeal squamous cell carcinoma 10.1 CDKN2A EGFR
46 chondromyxoid fibroma 10.1 CDKN2A VIM
47 oral cancer 10.1 CDKN2A EGFR
48 rhabdoid meningioma 10.1 NF2 VIM
49 hidradenocarcinoma 10.1 EGFR VIM
50 cytomegalovirus infection 10.1 CDKN2A EGFR

Graphical network of the top 20 diseases related to Malignant Peritoneal Mesothelioma:



Diseases related to Malignant Peritoneal Mesothelioma

Symptoms & Phenotypes for Malignant Peritoneal Mesothelioma

Human phenotypes related to Malignant Peritoneal Mesothelioma:

59 32 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dyspnea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002094
2 ascites 59 32 hallmark (90%) Very frequent (99-80%) HP:0001541
3 abdominal pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0002027
4 neoplasm 59 32 hallmark (90%) Very frequent (99-80%) HP:0002664
5 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
6 ileus 59 32 occasional (7.5%) Occasional (29-5%) HP:0002595
7 abnormality of coagulation 59 32 occasional (7.5%) Occasional (29-5%) HP:0001928
8 abdominal distention 59 32 hallmark (90%) Very frequent (99-80%) HP:0003270
9 peritonitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002586
10 edema of the lower limbs 59 32 occasional (7.5%) Occasional (29-5%) HP:0010741

UMLS symptoms related to Malignant Peritoneal Mesothelioma:


abdominal pain

GenomeRNAi Phenotypes related to Malignant Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.26 EGFR MUC1 NF2 VIM
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 8.8 EGFR MUC1 VIM

MGI Mouse Phenotypes related to Malignant Peritoneal Mesothelioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.35 BIRC5 CDKN2A EGFR NF2 VIM
2 respiratory system MP:0005388 8.92 CDKN2A EGFR NF2 VIM

Drugs & Therapeutics for Malignant Peritoneal Mesothelioma

Drugs for Malignant Peritoneal Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
2
Doxil Approved June 1999 Phase 3,Phase 2 31703
3 Ranpirnase Investigational Phase 3 196488-72-9
4 Antibiotics, Antitubercular Phase 3,Phase 2
5 Anti-Bacterial Agents Phase 3,Phase 2
6 Topoisomerase Inhibitors Phase 3,Phase 2
7
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
8
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
9
Gemcitabine Approved Phase 2 95058-81-4 60750
10
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
11
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
12
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 6055-19-2, 50-18-0 2907
13
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 439693 40926
14
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
15
leucovorin Approved Phase 2,Phase 1 58-05-9 6006 143
16
Fluorouracil Approved Phase 2 51-21-8 3385
17
Promethazine Approved, Investigational Phase 2 60-87-7 4927
18
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
19
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
20
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
21
Pancrelipase Approved, Investigational Phase 2 53608-75-6
22
Ranitidine Approved Phase 2 66357-35-5, 66357-59-3 3001055
23
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
24
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
25
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904 498142
26
Bevacizumab Approved, Investigational Phase 2 216974-75-3
27
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
28
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
30
Glutamic Acid Approved, Nutraceutical Phase 1, Phase 2 56-86-0 33032
31
Tremelimumab Investigational Phase 2,Phase 1 745013-59-6
32 Antiviral Agents Phase 2,Phase 1
33 Antimetabolites, Antineoplastic Phase 2
34 Immunologic Factors Phase 2,Phase 1
35 Immunosuppressive Agents Phase 2,Phase 1
36 Anti-Infective Agents Phase 2,Phase 1
37 Antimetabolites Phase 2
38 Antibodies, Monoclonal Phase 2,Phase 1
39 Immunoglobulins Phase 2,Phase 1
40 Antibodies Phase 2,Phase 1
41 Interferon-gamma Phase 2
42 Alkylating Agents Phase 2,Phase 1
43 Mitomycins Phase 2
44 interferons Phase 2,Phase 1
45 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
46 Antineoplastic Agents, Alkylating Phase 1, Phase 2
47 Antirheumatic Agents Phase 1, Phase 2,Phase 2
48 Immunotoxins Phase 1, Phase 2,Phase 2
49
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
50 Protein Kinase Inhibitors Phase 2,Phase 1

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
2 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
3 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Unknown status NCT00859469 Phase 2 Oxaliplatin/Gemcitabine
4 A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
5 Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
6 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Unknown status NCT01362790 Phase 1, Phase 2 Pentostatin;Cyclophosphamide
7 Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma Completed NCT01592383 Phase 2 erlotinib hydrochloride
8 Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma Completed NCT00061477 Phase 2 Pemetrexed;Gemcitabine
9 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Completed NCT01160458 Phase 2 IMC-A12
10 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
11 Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma Recruiting NCT03644550 Phase 2 LMB-100
12 Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study Recruiting NCT02588781 Phase 2 Pemetrexed
13 Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Recruiting NCT02535312 Phase 1, Phase 2 Cisplatin;Methoxyamine;Pemetrexed Disodium
14 Atezolizumab and Bevacizumab in Rare Solid Tumors Recruiting NCT03074513 Phase 2 Atezolizumab;Bevacizumab
15 Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma Active, not recruiting NCT01843374 Phase 2 Tremelimumab;Placebo
16 αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies Active, not recruiting NCT02151448 Phase 1, Phase 2 Celecoxib;Interferon Alfa-2b
17 Pembrolizumab in Treating Patients With Malignant Mesothelioma Active, not recruiting NCT02399371 Phase 2
18 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Enrolling by invitation NCT02040142 Phase 2 Mitomycin C
19 Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma Completed NCT02141347 Phase 1 Tremelimumab;MEDI4736
20 Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma Completed NCT00402766 Phase 1 Cisplatin;Imatinib Mesylate;Pemetrexed;Dexamethasone
21 Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma Recruiting NCT03608618 Phase 1
22 Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Active, not recruiting NCT02029690 Phase 1 ADI-PEG 20
23 Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma Active, not recruiting NCT02798536 Phase 1 LMB-100;nab-paclitaxel
24 Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors. Active, not recruiting NCT01439152 Phase 1 BAY94-9343;BAY94-9343 (Expansion);BAY94-9343 (1.8 mg/kg);BAY94-9343 (2.2 mg/kg)
25 CAR T Cells in Mesothelin Expressing Cancers Active, not recruiting NCT03054298 Phase 1
26 Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies Not yet recruiting NCT03546426 Phase 1 Pembrolizumab;Interleukin-2
27 Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma Suspended NCT03436732 Phase 1 LMB-100;SEL-110
28 Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays Completed NCT02834234
29 Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Completed NCT01812148
30 Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy Recruiting NCT01416714
31 Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed Recruiting NCT01617382
32 An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Recruiting NCT02754115
33 Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma Recruiting NCT01950572
34 French National Registry of Rare Peritoneal Surface Malignancies Active, not recruiting NCT02834169

Search NIH Clinical Center for Malignant Peritoneal Mesothelioma

Genetic Tests for Malignant Peritoneal Mesothelioma

Anatomical Context for Malignant Peritoneal Mesothelioma

MalaCards organs/tissues related to Malignant Peritoneal Mesothelioma:

41
Colon, Lung, Lymph Node, Testis, Liver, Pancreas, Pineal

Publications for Malignant Peritoneal Mesothelioma

Articles related to Malignant Peritoneal Mesothelioma:

(show top 50) (show all 298)
# Title Authors Year
1
Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. ( 29503128 )
2018
2
Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival. ( 29721724 )
2018
3
The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking. ( 29651664 )
2018
4
Malignant peritoneal mesothelioma in a woman with bilateral ovarian serous borderline tumour: Potential interactions between the two diseases. ( 29915796 )
2018
5
Malignant Peritoneal Mesothelioma in the setting of a Ventriculo-Peritoneal Shunt: A novel clinical presentation. ( 29899672 )
2018
6
Malignant peritoneal mesothelioma in patients with endometriosis. ( 29794065 )
2018
7
Malignant Peritoneal Mesothelioma Presenting as Mucinous Ascites. ( 29577057 )
2018
8
Analysis of prognostic factors of patients with malignant peritoneal mesothelioma. ( 29506546 )
2018
9
Prognostic Significance of Blood, Serum, and Ascites Parameters in Patients with Malignant Peritoneal Mesothelioma or Peritoneal Carcinomatosis. ( 29643915 )
2018
10
IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma. ( 30031101 )
2018
11
First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications. ( 30111295 )
2018
12
Malignant Peritoneal Mesothelioma in an Infant With Familial ATM Mutations. ( 30124550 )
2018
13
Malignant Peritoneal Mesothelioma: A Rare Cause of Ascites. ( 30349836 )
2018
14
Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives. ( 30386115 )
2018
15
ASO Author Reflections: Management of Malignant Peritoneal Mesothelioma. ( 30421065 )
2018
16
Malignant peritoneal mesothelioma: a review. ( 30450291 )
2018
17
Update on the management of malignant peritoneal mesothelioma. ( 30450299 )
2018
18
Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types. ( 30510965 )
2018
19
Malignant peritoneal mesothelioma: a review. ( 28706904 )
2017
20
Malignant peritoneal mesothelioma - a rare cause of laparotomy. ( 28702106 )
2017
21
A proposal of Brazilian Society of Surgical Oncology for standardizing cytoreductive surgery plus hypertermic intraperitoneal chemotherapy procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma. ( 29019584 )
2017
22
Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation. ( 28469343 )
2017
23
A case of malignant peritoneal mesothelioma suggesting the utility of combining double-contrast radiography and endoscopy with computed tomography for diagnosis. ( 28646342 )
2017
24
miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells. ( 28716051 )
2017
25
Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. ( 28189456 )
2017
26
Recurrence of Optimally Treated Malignant Peritoneal Mesothelioma with Cytoreduction and Heated Intraperitoneal Chemotherapy. ( 29027138 )
2017
27
Malignant peritoneal mesothelioma, clear cell variant, in a female and its differentiation from clear cell carcinoma. ( 28215643 )
2017
28
Unusual presentation of a late-onset recurrence of malignant peritoneal mesothelioma. ( 28264807 )
2017
29
Presentation of a malignant peritoneal mesothelioma in the forma of rough hepatic calcifications. ( 28480727 )
2017
30
Epidemiology of malignant peritoneal mesothelioma: A population-based study. ( 29080447 )
2017
31
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma. ( 28910456 )
2017
32
The diagnostic utility of PAX8 immunostaining of malignant peritoneal mesothelioma presenting as serous ovarian carcinoma: A single-center report of two cases. ( 28123552 )
2017
33
A Rare Case of Biphasic Malignant Peritoneal Mesothelioma with Refractory Ascites. ( 28381756 )
2017
34
Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. ( 28849389 )
2017
35
Erratum: A proposal of Brazilian Society of Surgical Oncology for standardizing cytoreductive surgery plus hypertermic intraperitoneal chemotherapy procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma. ( 29267565 )
2017
36
Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. ( 28324285 )
2017
37
First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. ( 28594258 )
2017
38
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma. ( 27858557 )
2016
39
A Case of Encapsulating Peritoneal Sclerosis Complicated by Malignant Peritoneal Mesothelioma. ( 27628605 )
2016
40
Renal cell carcinoma and malignant peritoneal mesothelioma after occupational asbestos exposure: case report. ( 27240221 )
2016
41
Asbestos content of lung tissue in patients with malignant peritoneal mesothelioma: A study of 42 cases. ( 27281118 )
2016
42
CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. ( 26810896 )
2016
43
Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. ( 27472649 )
2016
44
Malignant peritoneal mesothelioma and Crohn disease. ( 27484913 )
2016
45
Preventing recurrence of diffuse malignant peritoneal mesothelioma. ( 27486718 )
2016
46
A Histomorphologic Grading System That Predicts Overall Survival in Diffuse Malignant Peritoneal Mesothelioma With Epithelioid Subtype. ( 27438989 )
2016
47
Diagnosis and management of patients with malignant peritoneal mesothelioma. ( 26941986 )
2016
48
Diffuse malignant peritoneal mesothelioma presenting with psammomatous calcification on a cervical smear: A case report. ( 27773157 )
2016
49
A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma. ( 27187383 )
2016
50
CT differentiation of diffuse malignant peritoneal mesothelioma and peritoneal carcinomatosis. ( 26645426 )
2016

Variations for Malignant Peritoneal Mesothelioma

Expression for Malignant Peritoneal Mesothelioma

Search GEO for disease gene expression data for Malignant Peritoneal Mesothelioma.

Pathways for Malignant Peritoneal Mesothelioma

GO Terms for Malignant Peritoneal Mesothelioma

Biological processes related to Malignant Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of protein kinase activity GO:0006469 9.26 CDKN2A NF2
2 regulation of protein stability GO:0031647 9.16 CDKN2A NF2
3 cytokine-mediated signaling pathway GO:0019221 9.13 BIRC5 MUC1 VIM
4 negative regulation of cell-matrix adhesion GO:0001953 8.62 CDKN2A NF2

Sources for Malignant Peritoneal Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....